The study, published in Nature Chemical Biology, used a new tool that allowed researchers to study real-time metabolism in living cells under anaerobic conditions. Researchers identified how C. difficile jump-starts its metabolism by fermenting amino acids and simple sugars in a pathway that allows the bacteria to grow.
“Investigating real-time metabolism in microorganisms that only grow in environments lacking oxygen had been considered impossible,” co-corresponding author Lynn Bry, MD, PhD, director of the Massachusetts Host-Microbiome Center and associate medical director in pathology at Brigham and Women’s Hospital in Boston, said in the release. “Here, we’ve shown it can be done to combat C. difficile infections — and with findings applicable to clinical medicine.”
The study’s findings found new ways for small molecule drugs to counter C. difficile colonization and infection, “providing a new approach to rapidly define microbial metabolism for other applications,” researchers wrote.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.